(19)
(11)EP 0 298 654 A3

(12)EUROPEAN PATENT APPLICATION

(88)Date of publication A3:
07.02.1990 Bulletin 1990/06

(43)Date of publication A2:
11.01.1989 Bulletin 1989/02

(21)Application number: 88305934.7

(22)Date of filing:  30.06.1988
(51)International Patent Classification (IPC)4A61K 47/42, A61K 47/48
(84)Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(30)Priority: 07.07.1987 US 71861
18.04.1988 US 182530
21.06.1988 US 205748

(71)Applicant: HYBRISENS LTD.
Toronto Ontario M3J 1P3 (CA)

(72)Inventors:
  • Shami, Ezekiel Y.
    Toronto Ontario (CA)
  • Rothstein, Aser
    Toronto Ontario (CA)
  • Ramjeesingh, Mohabir
    Mississaugu Ontario (CA)

(74)Representative: Arthur, Bryan Edward et al
Withers & Rogers 4 Dyer's Buildings Holborn
London EC1N 2JT
London EC1N 2JT (GB)


(56)References cited: : 
  
      


    (54)Use of antibody/antigen interactions to protect or modulate biological activity


    (57) A complex can be produced, comprising (i) an molecule having a biological activity and (ii) an antibody entity recognizing the molecule, that displays biological activity which is inactivation-resistant, relative to that of the molecule. The biologically active molecule can be an enzyme, for example, and can be used to produce a complex with an antibody or antigen-binding protein that resists inactivation resulting from a physical, chemical or biological process. Thus, the inactivation-resistant complex displays prolonged activity under conditions characterized by disrupting temperature, the presence of a proteolytic enzyme, disrupting pH, the presence of an oxidizing agent and/or the presence of an alcohol, among others.





    Search report